Figure: Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study
"Seroprevalence estimates and 95% CIs for each week of the survey (A), daily confirmed COVID-19 cases reported in Geneva (B), and cumulative case counts per day and cumulative incidence rate of confirmed COVID-19 (C)". Red shading shows the sampling periods for each week.
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Risk of seropositivity across demographics: Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study
Table 2: Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study
Figure: Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study